Keywords: aventis, taxotere, shows, promise, early-stage, breast, cancer
Aventis' Taxotere shows promise in early-stage breast cancer, filings expected 2004
Article | 15 December 2003
Franco-German drug major Aventis' chemotherapy agent Taxotere(docetaxel) significantly improved the survival rate of women with early-stage breast cancer and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
